Knight Therapeutics Inc. (GUD.TO)
CAD 5.21
(-0.19%)
CAD 5.21
(-0.19%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 40.89 Million CAD | -5.64% |
| 2022 | 25.26 Million CAD | 41.38% |
| 2021 | 42.59 Million CAD | 48.73% |
| 2020 | 67.55 Million CAD | 56.87% |
| 2019 | 27.16 Million CAD | 216.8% |
| 2018 | -3.85 Million CAD | -79.63% |
| 2017 | -7.27 Million CAD | -14.38% |
| 2016 | -7.39 Million CAD | -167.03% |
| 2015 | -11.18 Million CAD | 1956.3% |
| 2014 | 131.16 Million CAD | 0.0% |
| 2013 | - CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 17.66 Million CAD | 120.4% |
| 2024 Q1 | 15.24 Million CAD | 175.58% |
| 2023 Q2 | 15.44 Million CAD | -29.71% |
| 2023 FY | - CAD | -5.64% |
| 2023 Q4 | 11.43 Million CAD | -41.65% |
| 2023 Q3 | 19.59 Million CAD | 26.84% |
| 2023 Q1 | 21.97 Million CAD | 64.64% |
| 2022 Q2 | 18.76 Million CAD | 29.78% |
| 2022 FY | - CAD | 41.38% |
| 2022 Q4 | 13.34 Million CAD | -2.26% |
| 2022 Q3 | 13.65 Million CAD | -27.21% |
| 2022 Q1 | 14.45 Million CAD | 109.98% |
| 2021 Q2 | 10.81 Million CAD | 64.26% |
| 2021 Q1 | 6.58 Million CAD | 767.33% |
| 2021 Q4 | 6.88 Million CAD | -62.03% |
| 2021 FY | - CAD | 48.73% |
| 2021 Q3 | 18.13 Million CAD | 67.69% |
| 2020 Q2 | 11.27 Million CAD | 73.43% |
| 2020 FY | - CAD | 56.87% |
| 2020 Q3 | 13.28 Million CAD | 17.85% |
| 2020 Q4 | 759 Thousand CAD | -94.29% |
| 2020 Q1 | 6.49 Million CAD | -85.21% |
| 2019 Q2 | -21.9 Million CAD | -269.73% |
| 2019 Q1 | -5.92 Million CAD | -276.1% |
| 2019 Q4 | 43.94 Million CAD | 1958.45% |
| 2019 FY | - CAD | 216.8% |
| 2019 Q3 | 2.13 Million CAD | 109.75% |
| 2018 FY | - CAD | -79.63% |
| 2018 Q4 | 3.36 Million CAD | 132.14% |
| 2018 Q2 | -4.33 Million CAD | -3.46% |
| 2018 Q1 | -4.19 Million CAD | -29.27% |
| 2018 Q3 | -10.46 Million CAD | -141.4% |
| 2017 Q3 | -666 Thousand CAD | -637.1% |
| 2017 Q2 | 124 Thousand CAD | 102.52% |
| 2017 Q1 | -4.91 Million CAD | 17.01% |
| 2017 FY | - CAD | -14.38% |
| 2017 Q4 | -3.24 Million CAD | -386.79% |
| 2016 FY | - CAD | -167.03% |
| 2016 Q1 | 387 Thousand CAD | -94.79% |
| 2016 Q4 | -5.92 Million CAD | -1309.18% |
| 2016 Q2 | -2.55 Million CAD | -761.24% |
| 2016 Q3 | 490 Thousand CAD | 119.15% |
| 2015 Q3 | 922 Thousand CAD | -35.75% |
| 2015 Q4 | 7.43 Million CAD | 706.4% |
| 2015 FY | - CAD | 1956.3% |
| 2015 Q1 | 1.55 Million CAD | 386.45% |
| 2015 Q2 | 1.43 Million CAD | -7.84% |
| 2014 Q4 | -543.58 Thousand CAD | -32.21% |
| 2014 Q3 | -411.16 Thousand CAD | -195.24% |
| 2014 Q2 | 431.69 Thousand CAD | 965.38% |
| 2014 Q1 | -49.88 Thousand CAD | 0.0% |
| 2014 FY | - CAD | 0.0% |
| 2013 FY | - CAD | 0.0% |
| 2013 Q3 | 34.45 Thousand CAD | 0.0% |
| 2012 Q3 | 63.36 Thousand CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Aurora Cannabis Inc. | 20.47 Million CAD | -99.751% |
| Avicanna Inc. | -7.35 Million CAD | 656.009% |
| Avant Brands Inc. | 4.83 Million CAD | -745.678% |
| Cardiol Therapeutics Inc. | -27.87 Million CAD | 246.69% |
| Crescita Therapeutics Inc. | 45 Thousand CAD | -90782.222% |
| MediPharm Labs Corp. | -10.47 Million CAD | 490.313% |
| OrganiGram Holdings Inc. | -207.61 Million CAD | 119.698% |
| Canopy Growth Corporation | -312.82 Million CAD | 113.073% |
| Willow Biosciences Inc. | -11.06 Million CAD | 469.741% |
| Auxly Cannabis Group Inc. | -10.82 Million CAD | 477.801% |